Skytrofa 13.3 mg/1
Lonapegsomatropin-tcgd · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Ascendis Pharma Endocrinology, Inc.
Skytrofa is a injection, powder, lyophilized, for solution containing lonapegsomatropin-tcgd at 13.3 mg/1, taken subcutaneous. Manufactured by Ascendis Pharma Endocrinology, Inc..
Key Facts
- Brand Name
- Skytrofa
- Generic Name
- Lonapegsomatropin-tcgd
- NDC Code (Product)
73362-011- Manufacturer
- Ascendis Pharma Endocrinology, Inc.
- Strength
- 13.3 mg/1
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761177
- Drug Class
- Recombinant Human Growth Hormone [EPC]
- Marketing Start
- 08/25/2021
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is Skytrofa used for?
Skytrofa contains Lonapegsomatropin-tcgd. It is a injection, powder, lyophilized, for solution taken subcutaneous. Consult your doctor for specific uses.
Is Skytrofa a controlled substance?
Skytrofa is not classified as a controlled substance by the DEA.
What is the generic name for Skytrofa?
The generic name for Skytrofa is Lonapegsomatropin-tcgd. There are no other listed brand versions of Lonapegsomatropin-tcgd.
What is the NDC code for Skytrofa 13.3 mg/1?
The NDC (National Drug Code) for Skytrofa 13.3 mg/1 is 73362-011, listed by Ascendis Pharma Endocrinology, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)